Novartis India Limited has completed its rebranding, officially changing its name to Evonile Pharma Limited effective October 1, 2026. The change follows shareholder approval at the company's 78th AGM and final certification from the Ministry of Corporate Affairs. This is an administrative identity update, with the company required to display its former name alongside the new identity for the next two years.
Novartis India Completes Rebranding to Evonile Pharma Limited
Novartis India Limited has officially completed its rebranding process, changing its name to Evonile Pharma Limited as of October 1, 2026.
The transition follows receipt of a fresh Certificate of Incorporation from the Ministry of Corporate Affairs.
Reader Takeaway: Administrative name change to Evonile Pharma Limited; no impact on core operations or financial standing.
What just happened
Following a Special Resolution passed by shareholders at the 78th Annual General Meeting on September 24, 2026, the company sought and received regulatory clearance for the name change. The Ministry of Corporate Affairs issued the final certificate on October 1, 2026.
Why this matters
The amendment to the Memorandum of Association (MoA) and Articles of Association (AoA) formally records the new corporate identity. While this represents a significant shift in corporate branding, the company continues to operate under the same legal framework and registration status.
Regulatory Requirements
To maintain transparency for stakeholders and regulators, the company is mandated to display its former name alongside the new name for a period of two years. Investors should update their records to reflect the transition to Evonile Pharma Limited for all future correspondence.
What to track next
Investors should monitor official exchange communications for updates regarding ticker symbols or trading name adjustments on the BSE and NSE platforms to ensure alignment with the new corporate entity name.